Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Delviks-Frankenberry Website

Krista A. Delviks-Frankenberry, Ph.D.

Selected Publications

1)  Delviks-Frankenberry K, Paprotka T, Cingöz O, Wildt S, Hu WS, Coffin JM, Pathak VK.
Generation of Multiple Replication-Competent Retroviruses through Recombination between PreXMRV-1 and PreXMRV-2.
J. Virol. 87: 11525-11537, 2013.
2)  Paprotka T, Delviks-Frankenberry KA, Cingöz O, Martinez A, Kung HJ, Tepper CG, Hu WS, Fivash MJ, Coffin JM, Pathak VK.
Recombinant origin of the retrovirus XMRV.
Science. 333: 97-101, 2011.
3)  Nikolenko GN, Delviks-Frankenberry KA, Pathak VK.
A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.
J. Virol. 84: 5238-49, 2010.
4)  Delviks-Frankenberry KA, Nikolenko GN, Boyer PL, Hughes SH, Coffin JM, Jere A, Pathak VK.
HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excision.
Proc. Natl. Acad. Sci. U.S.A. 105: 10943-8, 2008.
5)  Delviks KA, Hu WS, Pathak VK.
Psi- vectors: murine leukemia virus-based self-inactivating and self-activating retroviral vectors.
J. Virol. 71: 6218-24, 1997.
6)  Desimmie BA, Delviks-Frankenberrry KA, Burdick RC, Qi D, Izumi T, Pathak VK.
Multiple APOBEC3 Restriction Factors for HIV-1 and One Vif to Rule Them All.
J. Mol. Biol. 426: 1220-1245, 2014.
7)  Delviks-Frankenberry KA, Lengruber RB, Santos AF, Silveira JM, Soares MA, Kearney MF, Maldarelli F, Pathak VK.
Connection subdomain mutations in HIV-1 subtype-C treatment-experienced patients enhance NRTI and NNRTI drug resistance.
Virology. 435: 433-41, 2013.
8)  Murgai M, Thomas J, Cherepanova O, Delviks-Frankenberry K, Deeble P, Pathak V, Rekosh D, Owens G.
Xenotropic MLV envelope proteins induce tumor cells to secrete factors that promote the formation of immature blood vessels.
Retrovirology. 10(1): 34, 2013.
Full Text Article. [Journal]
9)  Ndongwe TP, Adedeji AO, Michailidis E, Ong YT, Hachiya A, Marchand B, Ryan EM, Rai DK, Kirby KA, Whatley AS, Burke DH, Johnson M, Ding S, Zheng YM, Liu SL, Kodama E, Delviks-Frankenberry KA, Pathak VK, Mitsuya H, Parniak MA, Singh K, Sarafianos SG.
Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase.
Nucleic Acids Res. 40: 345-59, 2012.
10)  Cingöz O, Paprotka T, Delviks-Frankenberry KA, Wildt S, Hu WS, Pathak VK, Coffin JM.
Characterization, mapping, and distribution of the two XMRV parental proviruses.
J. Virol. 86: 328-38, 2012.
11)  Delviks-Frankenberry K, Cingöz O, Coffin JM, Pathak VK.
Recombinant origin, contamination, and de-discovery of XMRV.
Curr Opin Virol. 2: 499-507, 2012.
12)  Delviks-Frankenberry KA, Chaipan C, Bagni R, Wyvill K, Yarchoan R, Pathak VK.
Lack of Detection of Xenotropic Murine Leukemia Virus-Related Virus in HIV-1 Lymphoma Patients.
Adv Virol. 2011: 797820, 2011.
13)  Delviks-Frankenberry K, Galli A, Nikolaitchik O, Mens H, Pathak VK, Hu WS.
Mechanisms and factors that influence high frequency retroviral recombination.
Viruses. 3: 1650-80, 2011.
14)  Kearney MF, Lee K, Bagni RK, Wiegand A, Spindler J, Maldarelli F, Pinto PA, Linehan WM, Vocke CD, Delviks-Frankenberry KA, Devere White RW, Del Prete GQ, Mellors JW, Lifson JD, Kewalramani VN, Pathak VK, Coffin JM, Le Grice SF.
Nucleic Acid, Antibody, and Virus Culture Methods to Detect Xenotropic MLV-Related Virus in Human Blood Samples.
Adv Virol. 2011: 272193, 2011.
15)  Lengruber RB, Delviks-Frankenberry KA, Nikolenko GN, Baumann J, Santos AF, Pathak VK, Soares MA.
Phenotypic characterization of drug resistance-associated mutations in HIV-1 RT connection and RNase H domains and their correlation with thymidine analogue mutations.
J. Antimicrob. Chemother. 66: 702-8, 2011.
16)  Chaipan C, Dilley KA, Paprotka T, Delviks-Frankenberry KA, Venkatachari NJ, Hu WS, Pathak VK.
Severe restriction of xenotropic murine leukemia virus-related virus replication and spread in cultured human peripheral blood mononuclear cells.
J. Virol. 85: 4888-97, 2011.
17)  Paprotka T, Venkatachari NJ, Chaipan C, Burdick R, Delviks-Frankenberry KA, Hu WS, Pathak VK.
Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs.
J. Virol. 84: 5719-29, 2010.
18)  Burdick R, Smith JL, Chaipan C, Friew Y, Chen J, Venkatachari NJ, Delviks-Frankenberry KA, Hu WS, Pathak VK.
P body-associated protein Mov10 inhibits HIV-1 replication at multiple stages.
J. Virol. 84: 10241-53, 2010.
19)  Delviks-Frankenberry KA, Nikolenko GN, Pathak VK.
The "Connection" Between HIV Drug Resistance and RNase H.
Viruses. 2: 1476-1503, 2010.
20)  Mbisa JL, Delviks-Frankenberry KA, Thomas JA, Gorelick RJ, Pathak VK.
Real-time PCR analysis of HIV-1 replication post-entry events.
Methods Mol. Biol. 485: 55-72, 2009.
21)  Delviks-Frankenberry KA, Nikolenko GN, Maldarelli F, Hase S, Takebe Y, Pathak VK.
Subtype-specific differences in the human immunodeficiency virus type 1 reverse transcriptase connection subdomain of CRF01_AE are associated with higher levels of resistance to 3"-azido-3"-deoxythymidine.
J. Virol. 83: 8502-13, 2009.
22)  Delviks-Frankenberry KA, Nikolenko GN, Barr R, Pathak VK.
Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3"-azido-3"-deoxythymidine resistance.
J. Virol. 81: 6837-45, 2007.
23)  Nikolenko GN, Delviks-Frankenberry KA, Palmer S, Maldarelli F, Fivash MJ, Coffin JM, Pathak VK.
Mutations in the connection domain of HIV-1 reverse transcriptase increase 3"-azido-3"-deoxythymidine resistance.
Proc. Natl. Acad. Sci. U.S.A. 104: 317-22, 2007.
24)  Frankenberry KA, Skinner H, Somasundar P, McFadden DW, Vona-Davis LC.
Leptin receptor expression and cell signaling in breast cancer.
Int. J. Oncol. 28: 985-93, 2006.
25)  Vona-Davis LC, Frankenberry KA, Waheed U, Peterson E, McFadden DW.
Expression of STAT3 and SOCS3 in pancreatic acinar cells.
J. Surg. Res. 127: 14-20, 2005.
26)  Vona-Davis L, Frankenberry K, Cunningham C, Riggs DR, Jackson BJ, Szwerc MF, McFadden DW.
MAPK and PI3K inhibition reduces proliferation of Barrett"s adenocarcinoma in vitro.
J. Surg. Res. 127: 53-8, 2005.
27)  Nikolenko GN, Svarovskaia ES, Delviks KA, Pathak VK.
Antiretroviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase increase template-switching frequency.
J. Virol. 78: 8761-70, 2004.
28)  Frankenberry KA, Somasundar P, McFadden DW, Vona-Davis LC.
Leptin induces cell migration and the expression of growth factors in human prostate cancer cells.
Am. J. Surg. 188: 560-5, 2004.
29)  Somasundar P, Frankenberry KA, Skinner H, Vedula G, McFadden DW, Riggs D, Jackson B, Vangilder R, Hileman SM, Vona-Davis LC.
Prostate cancer cell proliferation is influenced by leptin.
J. Surg. Res. 118: 71-82, 2004.
30)  Svarovskaia ES, Delviks KA, Hwang CK, Pathak VK.
Structural determinants of murine leukemia virus reverse transcriptase that affect the frequency of template switching.
J. Virol. 74: 7171-8, 2000.
31)  Delviks KA, Pathak VK.
Development of murine leukemia virus-based self-activating vectors that efficiently delete the selectable drug resistance gene during reverse transcription.
J. Virol. 73: 8837-42, 1999.
32)  Delviks KA, Pathak VK.
Effect of distance between homologous sequences and 3" homology on the frequency of retroviral reverse transcriptase template switching.
J. Virol. 73: 7923-32, 1999.
33)  Hu WS, Bowman EH, Delviks KA, Pathak VK.
Homologous recombination occurs in a distinct retroviral subpopulation and exhibits high negative interference.
J. Virol. 71: 6028-36, 1997.
Click Here to View Collapsed Bibliography.

This page was last updated on 7/11/2014.